Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRONTIER 4: MEDI3506 in moderate to severe COPD with chronic bronchitis
MOH_2021-05-04_009944Phase 2Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) and chronic bronchitis (CB) comparing MEDI3506 with Placebo (2 arms). Primary endpoint: FEV1. Planned start Mar 2021; status: not yet recruiting.
02
Drugs
tozorakimab
03
Conditions
chronic obstructive pulmonary disease (COPD)chronic bronchitis (CB)
Beyond the preview
Go deeper on MOH_2021-05-04_009944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-05-04_009944.